Join the club for FREE to access the whole archive and other member benefits.

LIfT BioSciences

Biotechnology company that develops a portfolio of potentially life-saving immuno-oncology cell therapies

LIfT Biosciences is a biotech bringing to market a first-in-class 'off-the-shelf' innate cell therapy called Neutrophil based Leukocyte Infusion Therapy (N-LIfT). N-LIfT is the world's first neutrophil-based cancer therapeutic product that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain. N-LIfT uses a special type of N1a neutrophil with special cancer killing and immune recruitment capabilities, whilst additionally maintaining minimal damage to healthy cells. 

Our vision is to develop the world’s first cell bank of mass produced ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for delivering complete remission in all solid tumours. Our planned Series A in 2021 will fund our manufacture scale-up and phase I/II orphan PoC trial is in some of the most challenging solid tumours e.g. Pancreatic (PDAC), Liver (HCC) and Lung (NSCLC).

Visit website: https://www.liftbiosciences.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

People at LIfT BioSciences

Company Representative

Founder and Chief Executive Officer of LIfT BioSciences.

LIfT BioSciences News

LIfT BioSciences cell therapy infiltrates pancreatic tumour in mice models

LIfT BioSciences - 09-Nov-2020

N-LIfT is an allogenic cell therapy which recruits patient's own immune cells against cancers

Read more...

Radical new cancer treatment to be trialled next year

ITV News - 24-Nov-2017

Uses cancer-killing cells from people with the strongest immune systems. Neutrophil cells form p...

Read more...